BACKGROUND:Hypereosinophilic syndromes (HESs) are chronic disorders that require long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are usually effective, yet many patients become corticosteroid refractory or develop corticosteroid toxicity. Mepolizumab, a humanized monoclonal anti-IL-5 antibody, showed corticosteroid-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, corticosteroid-responsive subjects with HESs. OBJECTIVE: We evaluated long-term safety and efficacy of mepolizumab (750 mg) in HES. METHODS: MHE100901 is an open-label extension study. The primary end point was the frequency of adverse events (AEs). Optimal dosing frequency, corticosteroid-sparing effect of mepolizumab, and development of antimepolizumab antibodies were also explored. RESULTS:Seventy-eight subjects received 1 to 66mepolizumab infusions each (including mepolizumab infusions received in the placebo-controlled trial). Mean exposure was 251 weeks (range, 4-302 weeks). The most common dosing interval was 9 to 12 weeks. The incidence of AEs was 932 events per 100 subject-years in the first year, declining to 461 events per 100 subject-years after 48 months. Serious AEs, including 1 death, were reported by the investigator as possibly due to mepolizumab in 3 subjects. The median daily prednisone dose decreased from 20.0 to 0 mg in the first 24 weeks. The median average daily dose for all subjects over the course of the study was 1.8 mg. Sixty-two percent of subjects were prednisone free without other HES medications for ≥ 12 consecutive weeks. No neutralizing antibodies were detected. Twenty-four subjects withdrew before study completion for death (n = 4), lack of efficacy (n = 6), or other reasons. CONCLUSION:Mepolizumab was well tolerated and effective as a long-term corticosteroid-sparing agent in PDGFRA-negative HES. Published by Mosby, Inc.
RCT Entities:
BACKGROUND:Hypereosinophilic syndromes (HESs) are chronic disorders that require long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are usually effective, yet many patients become corticosteroid refractory or develop corticosteroid toxicity. Mepolizumab, a humanized monoclonal anti-IL-5 antibody, showed corticosteroid-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, corticosteroid-responsive subjects with HESs. OBJECTIVE: We evaluated long-term safety and efficacy of mepolizumab (750 mg) in HES. METHODS:MHE100901 is an open-label extension study. The primary end point was the frequency of adverse events (AEs). Optimal dosing frequency, corticosteroid-sparing effect of mepolizumab, and development of antimepolizumab antibodies were also explored. RESULTS: Seventy-eight subjects received 1 to 66 mepolizumab infusions each (including mepolizumab infusions received in the placebo-controlled trial). Mean exposure was 251 weeks (range, 4-302 weeks). The most common dosing interval was 9 to 12 weeks. The incidence of AEs was 932 events per 100 subject-years in the first year, declining to 461 events per 100 subject-years after 48 months. Serious AEs, including 1 death, were reported by the investigator as possibly due to mepolizumab in 3 subjects. The median daily prednisone dose decreased from 20.0 to 0 mg in the first 24 weeks. The median average daily dose for all subjects over the course of the study was 1.8 mg. Sixty-two percent of subjects were prednisone free without other HES medications for ≥ 12 consecutive weeks. No neutralizing antibodies were detected. Twenty-four subjects withdrew before study completion for death (n = 4), lack of efficacy (n = 6), or other reasons. CONCLUSION:Mepolizumab was well tolerated and effective as a long-term corticosteroid-sparing agent in PDGFRA-negative HES. Published by Mosby, Inc.
Authors: Craig M Lilly; Andrew Churg; Mark Lazarovich; Romain Pauwels; Leslie Hendeles; Lanny J Rosenwasser; Dennis Ledford; Michael E Wechsler Journal: J Allergy Clin Immunol Date: 2002-01 Impact factor: 10.793
Authors: Peter Valent; Amy D Klion; Hans-Peter Horny; Florence Roufosse; Jason Gotlib; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Joseph H Butterfield; Wolfgang R Sperr; Karl Sotlar; Peter Vandenberghe; Torsten Haferlach; Hans-Uwe Simon; Andreas Reiter; Gerald J Gleich Journal: J Allergy Clin Immunol Date: 2012-03-28 Impact factor: 10.793
Authors: Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich Journal: N Engl J Med Date: 2008-03-16 Impact factor: 91.245
Authors: Parameswaran Nair; Marcia M M Pizzichini; Melanie Kjarsgaard; Mark D Inman; Ann Efthimiadis; Emilio Pizzichini; Frederick E Hargreave; Paul M O'Byrne Journal: N Engl J Med Date: 2009-03-05 Impact factor: 91.245
Authors: Princess U Ogbogu; Bruce S Bochner; Joseph H Butterfield; Gerald J Gleich; Johannes Huss-Marp; Jean Emmanuel Kahn; Kristin M Leiferman; Thomas B Nutman; Florian Pfab; Johannes Ring; Marc E Rothenberg; Florence Roufosse; Marie-Helene Sajous; Javed Sheikh; Dagmar Simon; Hans-Uwe Simon; Miguel L Stein; Andrew Wardlaw; Peter F Weller; Amy D Klion Journal: J Allergy Clin Immunol Date: 2009-12 Impact factor: 10.793